The RNA‐binding protein (RBP) Musashi‐2 (MSI2) is overexpressed in many cancers, including colorectal adenocarcinomas,1, 2, 3 breast,4, 5 hematologic malignancies,6, 7, 8, 9, 10, 11, 12 lung,13 glioblastoma,14 and pancreatic cancers.15, 16, 17 As such, it mediates mRNA stability and translation of proteins involved in oncogenic pathways.18, 19, 20 Overexpression and knockdown studies indicate that MSI2 is a promising therapeutic target for cancer.3, 13, 16, 21, 22. This evidence concerns the gene MSI2 and hematologic disorder.